On Feb 27, Pharmaniaga announced that it had fallen under the PN17 classification after it recorded its largest quarterly net loss of RM664.39 million in the fourth quarter ending Dec 31, 2022.
Last week, the main association representing pharmaceutical companies in Malaysia sounded the alarm over the group’s financial woes, saying it could affect patients’ access to medicine if not quickly resolved. On Feb 27, Pharmaniaga announced that it had fallen under the PN17 classification after it recorded its largest quarterly net loss of RM664.39 million in the fourth quarter ending Dec 31, 2022.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: